APA and AAN guidelines: VMAT2 inhibitor as first-line treatment for TD1,2

Only VMAT2 inhibitor indicated for TD with no dose restrictions for—or recommendations against—use in patients taking strong CYP3A4/5 inducers or inhibitors3

Patients with TD take a variety of concomitant medications—it is important to consider metabolic pathways in the treatment of tardive dyskinesia (TD).3,4

  • ~50% of drugs are metabolized through the CYP3A4/5 pathway, which may increase the likelihood of drug-drug interactions with subsequent medications in the treatment plan4,5
  • AUSTEDO is metabolized primarily through CYP2D6—with minor contributions of CYP3A4/5 and other enzymes to form several minor metabolites3

In the pivotal studies, most patients taking AUSTEDO were able to stay on their concomitant psychiatric medications6

Coadministration per pathway dosing for AUSTEDO and INGREZZA® (valbenazine).

Coadministration per pathway dosing for AUSTEDO and INGREZZA® (valbenazine).

In patients who are poor CYP2D6 metabolizers or are taking strong CYP2D6 inhibitors, the total daily dosage of AUSTEDO should not exceed 36 mg (maximum single dose of 18 mg).3

  • For a list of medications that can help determine potential drug-drug interactions with your patients’ concomitant treatments, see the FlockhartTM Table

AUSTEDO has a range of dosing options for patients on concomitant medications3

TD Talks Logo.

Watch Dr.
Rakesh Jain discuss drug metabolism as a crucial consideration for TD treatment

AAN, American Academy of Neurology; APA, American Psychiatric Association; VMAT2, vesicular monoamine transporter 2.

REFERENCES: 1. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. 3rd ed. American Psychiatric Association; 2021. 2. Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67-75. 3. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 4. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(3):391-396. 5. Lee S-J, Goldstein JA. Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities. Drug Metab Pharmacokinet. 2012;27(6):663-667. 6. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 7. INGREZZA® (valbenazine) capsules Prescribing Information. San Diego, CA: Neurocrine Biosciences, Inc.; April 2021.